Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT01162395 Completed - Prostate Cancer Clinical Trials

Open Label Prostate Cancer Study

Start date: August 2010
Phase: Phase 1
Study type: Interventional

The main purpose of the study is to investigate the safety and tolerability of AZD3514 when given orally to patients with castration-resistant prostate cancer (CRPC)

NCT ID: NCT01162135 Completed - Prostate Cancer Clinical Trials

Digoxin for Recurrent Prostate Cancer

Start date: September 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effectiveness of dioxin on prohibiting prostate cancer progression as measured by PSADT (prostate-specific antigen doubling time).

NCT ID: NCT01161563 Completed - Prostate Cancer Clinical Trials

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Start date: July 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.

NCT ID: NCT01160705 Completed - Prostate Cancer Clinical Trials

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

Start date: November 2009
Phase:
Study type: Observational

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This clinical trial is studying blood samples in predicting how patients with prostate cancer will respond to treatment with docetaxel.

NCT ID: NCT01148069 Completed - Prostate Cancer Clinical Trials

Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers

TARGET
Start date: July 30, 2010
Phase: Phase 2
Study type: Interventional

Standard treatment of locally-advanced prostate cancers consists in the association of radiotherapy of prostate and seminal vesicles (SV) and androgen deprivation (AD) for 3 years. This treatment is usually preceded by pelvic lymphadenectomy to assess the possible extension to lymph nodes of prostatic cancer and to avoid irradiating the pelvis in case of no lymph node involvement. However, radiotherapy leads usually to about 30% of grade ≥2 risk of bladder and/or rectal toxicity. This risk particularly depends on the radiation volume. In the aim of lowering the toxicity, the treatment in this study will associate: - pelvic lymph node dissection and resection of seminal vesicles, allowing decreasing the radiation target volume to the prostate only (and not to irradiate the SV); - a high-precision radiotherapy technique combining Intensity Modulated Radiation Therapy (IMRT) and Image-Guided Radiation Therapy (IGRT).

NCT ID: NCT01146340 Completed - Prostate Cancer Clinical Trials

Safety and Efficacy Study of Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer

PHART6
Start date: May 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of a short course of radiotherapy (40 Gy / 5 fractions / 29 days) for the treatment of low- and intermediate-risk prostate cancer.

NCT ID: NCT01144897 Completed - Prostate Cancer Clinical Trials

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

Start date: May 2010
Phase: Phase 1
Study type: Interventional

One purpose of this research study is to examine if a special type of imaging test, a positron emission tomography (PET) scan using the radioactive material [C-11] acetate, will be helpful in detecting prostate cancer lesions in subjects with castrate-resistant prostate cancer (CRPC). This PET scan will be combined with a computed tomography (CT) scan taken during the same imaging session. The other purpose of the PET-CT scan using [C-11] acetate (PET Acetate Scan) is to assist in identifying who is responding to the treatment (docetaxel chemotherapy).

NCT ID: NCT01138527 Completed - Prostate Cancer Clinical Trials

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

PCa-MAP
Start date: June 2010
Phase:
Study type: Observational

The primary objective of this prospective multi-centre study is to prove the diagnostic accuracy of in vivo 3T multi-modality Magnetic Resonance Imaging (high resolution T2-weighted MRI, DCE-MRI, MRSI and DWI techniques) in distinguishing carcinoma from other prostate tissue. The gold standard for distinguishing the tissue types is the analysis of whole-mount sections of the resected prostate by a genitourinary histopathologist.

NCT ID: NCT01136226 Completed - Prostate Cancer Clinical Trials

Evaluate Recovery of Testosterone for Patients Using Eligard

Eligard
Start date: October 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.

NCT ID: NCT01135849 Completed - Breast Cancer Clinical Trials

B-Receptor Signaling in Cardiomyopathy

Start date: November 2008
Phase: N/A
Study type: Observational

We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether certain individuals have increased susceptibility to cardiac injury.